ClinicalTrials.gg
CompletedNCT03785964DeFiUpdated Aug 20, 2026Results posted

Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)

A Phase 3 interventional study of Nirogacestat oral tablet and Placebo Oral Tablet in Desmoid Tumor and Aggressive Fibromatosis, sponsored by SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany. Completed at 52 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany (part of Merck KGaA, Darmstadt, Germany) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies in Desmoid Tumors with a site in United States — 6 open to participants now, 9 under way, 1 of them phase 3. Desmoid Tumors · United States.

Enrollment
5th of 24
142 · median 43
Started
2019
the only one that year
Phase 3
3 of 33
none open now
Registered
23rd of 33
by date
Lead sponsor
2 of 33
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Among the 33 studies in Desmoid Tumors with a site in United States, this one is the 5th largest by enrollment of the 24 interventional ones that give a count, is the only one that started in 2019, is one of 3 in phase 3, and was the 23rd registered.

Desmoid Tumors

71 studies on the registry are indexed under Desmoid Tumors; 21 are open to participants now.

Browse Desmoid Tumors studies →

Open to participants now

6 of the 33 studies in Desmoid Tumors with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Desmoid Tumors studies recruiting now, 13 (76%) set no upper age limit and 4 (24%) stop at 75 or younger; 6 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Desmoid Tumors with a site in United States, or all of them as a file.
02

Study summary

This study evaluates nirogacestat (PF-03084014) in the treatment of desmoid tumor/aggressive fibromatosis (DT/AF). In the double-blind phase, half of the participants will receive nirogacestat while the other half will receive placebo. Once participants are eligible to roll into the open-label phase, they will receive nirogacestat.

Read the detailed description

Desmoid tumors, also referred to as aggressive fibromatosis, are rare, locally invasive, slow growing soft tissue tumors. Although considered benign because of their inability to metastasize, desmoid tumors can cause significant morbidity and occasionally mortality in patients.

Nirogacestat (PF-03084014) is a potent, small molecule, selective, reversible, noncompetitive inhibitor of γ-secretase (GS) with a potential antitumor activity.

Nirogacestat is being investigated for the treatment of desmoid tumors due to its ability to bind to GS, blocking proteolytic activation of Notch receptors. Previous clinical study data have shown that Notch signaling plays an important role in cancer development. Hence, inhibition of Notch signaling is an important strategy for therapeutic treatment.

03

Conditions studied

  • Desmoid Tumor
  • Aggressive Fibromatosis

Browse trials for

Keywords

  • PF-03084014
  • GSI
  • gamma secretase inhibitor
  • notch pathway
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Double-Blind Key Inclusion Criteria:

  • Participant has confirmed DT/AF (by local pathologist prior to ) that has progressed by ≥ 20% as measured by v1.1 within 12 months of the screening visit scan.
  • Participant has:

    1. Treatment naïve, measurably progressing DT/AF that is deemed not amenable to surgery without the risk of significant morbidity; OR
    2. Recurrent, measurably progressing DT/AF following at least one ; OR
    3. , measurably progressing DT/AF following at least one line of therapy.
  • Participant has a DT/AF tumor where continued progressive disease will not result in immediate significant risk to the participant.
  • Participant agrees to provide archival or new tumor tissue for re-confirmation of disease.
  • If participant is currently being treated with any therapy for the treatment of DT/AF, this must be completed at least 28 days (or 5 half-lives, whichever is longer) prior to first dose of study treatment. All toxicities from prior therapy must be resolved to ≤Grade 1 or clinical baseline.
  • Participants who are receiving chronic nonsteroidal anti-inflammatory drugs (NSAIDs) as treatment for conditions other than DT/AF must be receiving them prior to the documented DT/AF progressive disease (inclusion criteria 2) and on a stable dose for at least 28 days prior to first dose of study treatment.
  • Participant has an (ECOG) performance status ≤ 2 at screening.
  • Participant has adequate organ and bone marrow function.

Double-Blind Key Exclusion Criteria:

  • Participant has known malabsorption syndrome or preexisting gastrointestinal conditions that may impair absorption of nirogacestat.
  • Participant has experienced any of the following within 6 months of signing informed consent: cardiac disease ( Class III or IV), myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, , or symptomatic pulmonary embolism.
  • Participant has an abnormal at screening.
  • Participant is using concomitant medications that are known to prolong the QT/QTcF interval including Class Ia and Class III antiarrhythmics at the time of informed consent. Non-antiarrhythmic medications which may prolong the QT/QTcF interval are allowed provided the participant does not have additional risk factors for Torsades de Pointes (TdP)
  • Participant has congenital long QT syndrome.
  • Participant has a history of additional risk factors for Torsades de Pointes (TdP) (e.g., heart failure, hypokalemia, family history of Long QT Syndrome).
  • Participant has had lymphoma, leukemia, or any within the past 5 years at the time of informed consent, except for any locally recurring cancer that has been treated curatively (e.g., resected basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast), with no evidence of disease for 3 years at the time of informed consent.
  • Participant has current or chronic history of liver disease or known hepatic or biliary abnormalities (except for Gilbert's syndrome or asymptomatic gallstones).
  • Participant previously received or is currently receiving therapy with GS inhibitors or anti-Notch antibody therapy.
  • Participant is currently using any treatment for DT/AF including tyrosine kinase inhibitors (TKIs), NSAIDs (chronic daily use) or any treatment 28 days (or 5 half-lives, whichever is longer) prior to the first dose of study treatment.

OR

Participant has started any treatment for DT/AF after the documented DT/AF progressive disease.

  • Participant is currently using or anticipates using food or drugs that are known strong/moderate cytochrome P450 3A4 () inhibitors, or strong CYP3A inducers within 14 days prior to the first dose of study treatment.
  • Participant has a positive antibody test.
  • Participant has presence of surface antigen at screening.
  • Participant has a positive antibody or Hepatitis C ribonucleic acid (RNA) test result at screening or within 3 months prior to starting study treatment.
  • Participant is unable to tolerate MRI or for whom MRI is .
  • Participant with active or chronic infection at the time of informed consent and during the screening period.
  • Participant has experienced other severe acute or chronic medical or psychiatric conditions within 1 year of signing informed consent.
  • Participant is unable to comply with study related procedures (including, but not limited to, the completion of electronic patient report outcomes (ePROs), or the ePRO questionnaires are not available in the participant's preferred language).

Open-Label Key Inclusion

  • Participant is enrolled in the double-blind phase when the estimated number of PFS events have been observed and the primary PFS analysis has been completed; OR
  • Participant is randomized to receive placebo in the double-blind phase and Central Imaging Review determines that the participant has radiographic progressive disease; OR
  • Participant is randomized to receive nirogacestat in the double-blind phase and Central Imaging Review determines that the participant has radiographic progressive disease but the participant is deriving clinical benefit without significant toxicity (as determined by the investigator).
  • Participant has adequate organ and bone marrow function

Open-Label Key Exclusion

  • Participant requires surgery to prevent organ dysfunction.
  • Participant has prematurely discontinued from the double-blind phase for any reason other than radiographic progressive disease (as determined by Central Imaging Review).
  • Participant developed a concurrent illness/condition that, in the opinion of the investigator, would represent a risk to overall health if they enroll in this study.
  • Participant has initiated a new treatment for DT/AF after the Central Imaging Review determines that a participant has radiographic progressive disease.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
142 participants (actual)

Study arms

  • Experimental
    Double-Blind Phase - Nirogacestat

    Nirogacestat 150 mg by mouth, twice daily

    Drug: Nirogacestat oral tablet

  • Placebo comparator
    Double-Blind Phase - Placebo

    Placebo by mouth, twice daily

    Drug: Placebo Oral Tablet

  • Experimental
    Open-Label Phase - Nirogacestat

    Nirogacestat 150 mg by mouth, twice daily

    Drug: Nirogacestat oral tablet

Interventions

  • Nirogacestat tablet

    Also known as: PF-03084014

  • DrugPlacebo Oral Tablet

    Sugar pill manufactured to mimic nirogacestat 50 mg tablet

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) Defined as the Time From Randomization Until Date of Assessment of Progression or Death by Any Cause.

    Progression will be determined radiographically using RECIST v1.1 (Eisenhauer, 2009) or clinically as assessed by the investigator. Clinical progression is defined as the onset or worsening of symptoms resulting in a global deterioration of health status causing the permanent discontinuation from study treatment and the initiation of emergent treatment (e.g., radiotherapy, surgery, or systemic therapy including chemotherapy or tyrosine kinase inhibitors) for DT/AF. Events of clinical progression will be adjudicated by an independent blinded central Endpoint Adjudication Committee (EAC) which will qualify events of clinical progression for inclusion in the PFS endpoint prior to study unblinding according to an EAC Review Charter.

    Time frame: On the first day of every 3 cycles (each cycle is 28 days) until disease progression is observed or death, whichever comes first, assessed up to approximately 2 years

Secondary outcomes

  1. Objective Response Rate Using RECIST Version 1.1 Criteria.

    Objective response rate (ORR) is defined as the proportion of participants having a confirmed Best Overall Response (BOR) of CR or PR by central reader using RECIST v1.1 criteria. Responses obtained up until progression, or last evaluable assessment in the absence of progression, will be included in the assessment of ORR. However, any responses, which occurred after a new anticancer therapy was received, will not be included. ORR is presented by percentages of responders.

    Time frame: On the first day of every 3 cycles (each cycle is 28 days) through study completion, an average of 2 years

  2. Change From Baseline at Cycle 10 in the Brief Pain Inventory (BPI) Average Pain Intensity (API) Score.

    The Brief Pain Inventory consists of 9 questions and utilizes a 11-point Numerical pain Rating Scale from 0-10 measuring severity from "no pain" to "pain as bad as you can imagine," with a 24-hour recall period. Average Pain Intensity is calculated as the 7-day average (when results on at least 4 days for a VISIT are available) of Brief Pain Inventory Question #3 - Worst Pain in last 24 hours. A lower score indicates greater pain relief. The minimum and maximum of the actual score are (0, 8) for Nirogacestat and (0,9) for Placebo, respectively. A positive change from Baseline value indicates worsening of Average Pain Intensity and a negative change from Baseline value indicates improvement of Average Pain Intensity. The minimum and maximum of change from baseline score are (-7, 3) for Nirogacestat and (-5, 5) for Placebo, respectively.

    Time frame: Daily for the last 7 days of every cycle (each cycle is 28 days) through study completion, an average of 2 years

  3. Change From Baseline at Cycle 10 in the GOunder/Desmoid Tumor Research Tumor Foundation (DTRF) DEsmoid Tumor Symptom Scale (DTSS) - Total Score

    The DEsmoid Tumor Symptom Scale is an 11-point, numeric rating scale from 0 to 10 to measure severity from "none" to "as bad as you can imagine," with a 24-hour recall period. The Total Symptom Score is calculated as the mean of Pain items (Items 1-3) as a single score, then a mean of this with items 4-7). Weekly summary scores will be created by averaging the daily scores over the 7 days period prior to each visit. A weekly score will be derived only if 4 or more out of 7 days period have non-missing scores. The weekly summary score will be used in analyses. If no weekly summary score is calculable, the participant will have data considered as missing at that visit. Higher scores represent worse symptom severity. The minimum and maximum of the actual score are (0,7) for Nirogacestat and (0,10) for Placebo. A positive change from Baseline value indicated worsening of symptoms. The minimum and maximum of change from baseline are (-6,1) for Nirogacestat and (-4,5) for Placebo.

    Time frame: Daily for the last 7 days of every cycle (each cycle is 28 days) through study completion, an average of 2 years

  4. Change From Baseline in the GOunder/Desmoid Tumor Research Foundation (DTRF) DEsmoid Tumor Impact Scale (DTIS) - Physical Functioning Domain Score

    The items are evaluated on a 5-point Likert Scale ranging from "none of the time" to "all of the time" to measure frequency, with a 7-day recall period. The Physical Function Domain Score are calculated as the average Item 01 Moving, Item 02 Reaching (Freq), Item 06 Vigorous Activity, Item 7 Moderate Activity, and Item 08 Accomplished Less. Higher scores represent worst impact severity. The minimum and maximum of the actual score are (1, 5) for Nirogacestat and (1,5) for Placebo, respectively. A positive change from baseline value indicates worsening impact and a negative change from baseline value indicates improvement in impact. The minimum and maximum of change from baseline score are (-3, 0) for Nirogacestat and (-1, 2) for Placebo, respectively.

    Time frame: On the last day of every cycle (each cycle is 28 days) through study completion, average of 2 years.

  5. Change From Baseline at Cycle10 in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status/Quality of Life (GHS/QoL) Scale.

    The EORTC Quality of Life Questionnaire-Core 30 version 3.0 was used with a 7-day recall period. It consists of 30 questions with all items scored 1 ("not at all") to 4 ("very much") except for the 2 items contributing to the global health status/QoL, which are scored 1 ("very poor") to 7 ("excellent"). The instrument yields the following scales:5 functional scales, 3 symptom scales, and a global health status/quality of life scale. A high score for the global health status/QoL represents a high QoL. The minimum and maximum of the actual score are (33, 100) for Nirogacestat and (8,92) for Placebo, respectively. A positive change from baseline indicated improvement of global health status and a negative change from baseline value indicated worsening of global health status. The minimum and maximum of change from baseline score are (-58, 67) for Nirogacestat and (-67, 42) for Placebo, respectively.

    Time frame: Last day of every cycle (each cycle is 28 days) through study completion, an average of 2 years

  6. Change From Baseline at Cycle 10 in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Physical Functioning

    The EORTC Quality of Life Questionnaire-Core 30 version 3.0 was used with a 7-day recall period. It consists of 30 questions with all items scored 1 ("not at all") to 4 ("very much") except for the 2 items contributing to the global health status/QoL, which are scored 1 ("very poor") to 7 ("excellent"). The instrument yields the following scales:5 functional scales, 3 symptom scales, and a global health status/quality of life scale. A high score for a Physical functional scale represents a high/healthy level of functioning. The minimum and maximum of the actual score are (27, 100) for Nirogacestat and (7,100) for Placebo, respectively. A positive change from baseline indicated improvement of global health status and a negative change from baseline value indicated worsening of physical functioning scores. The minimum and maximum of change from baseline score are (-7, 40) for Nirogacestat and (-40, 27) for Placebo, respectively.

    Time frame: Last day of every cycle (each cycle is 28 days) through study completion, an average of 2 years

  7. Change From Baseline at Cycle 10 in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Role Functioning.

    The EORTC Quality of Life Questionnaire-Core 30 version 3.0 was used with a 7-day recall period. It consists of 30 questions with all items scored 1 ("not at all") to 4 ("very much") except for the 2 items contributing to the global health status/QoL, which are scored 1 ("very poor") to 7 ("excellent"). The instrument yields the following scales:5 functional scales, 3 symptom scales, and a global health status/quality of life scale. A positive change from baseline indicated improvement of global health status and a negative change from baseline value indicated worsening of global health status and functioning scores. The minimum and maximum of change from baseline score are (-17, 83) for Nirogacestat and (-100, 50) for Placebo, respectively.

    Time frame: Last day of every cycle (each cycle is 28 days) through study completion, an average of 2 years

07

Results

Posted Jun 12, 2024

Participant flow

Participant flow — Overall Study
MilestoneDouble-Blind Phase - NirogacestatDouble-Blind Phase - Placebo
Started7072
Treated (safety population)6972
Completed1235
Not completed5837
Withdrew: Adverse event141
Withdrew: Unqualified clinical progression11
Withdrew: Participant non-compliance11
Withdrew: Not treated10
Withdrew: Other reason511
Withdrew: Ongoing (still on treatment) pertains to treatment status at the time of the primary analysis3623

Outcome measures

PrimaryProgression Free Survival (PFS) Defined as the Time From Randomization Until Date of Assessment of Progression or Death by Any Cause.

Progression will be determined radiographically using RECIST v1.1 (Eisenhauer, 2009) or clinically as assessed by the investigator. Clinical progression is defined as the onset or worsening of symptoms resulting in a global deterioration of health status causing the permanent discontinuation from study treatment and the initiation of emergent treatment (e.g., radiotherapy, surgery, or systemic therapy including chemotherapy or tyrosine kinase inhibitors) for DT/AF. Events of clinical progression will be adjudicated by an independent blinded central Endpoint Adjudication Committee (EAC) which will qualify events of clinical progression for inclusion in the PFS endpoint prior to study unblinding according to an EAC Review Charter.

Time frame:
On the first day of every 3 cycles (each cycle is 28 days) until disease progression is observed or death, whichever comes first, assessed up to approximately 2 years
Reported as:
Median · Months
Progression Free Survival (PFS) Defined as the Time From Randomization Until Date of Assessment of Progression or Death by Any Cause.
MonthsDouble-Blind Phase - NirogacestatDouble-Blind Phase - Placebo
Progression Free Survival (PFS) Defined as the Time From Randomization Until Date of Assessment of Progression or Death by Any Cause.NA (NA to NA)15.1 (8.4 to NA)
Statistical analysis
  • Double-Blind Phase - Nirogacestat vs Double-Blind Phase - Placebo · Log Rank · p = < 0.001 · Hazard ratio (hr): 0.29 · 95% CI 0.15 to 0.55p-value was from a one-sided stratified log-rank test with placebo as reference.
SecondaryObjective Response Rate Using RECIST Version 1.1 Criteria.

Objective response rate (ORR) is defined as the proportion of participants having a confirmed Best Overall Response (BOR) of CR or PR by central reader using RECIST v1.1 criteria. Responses obtained up until progression, or last evaluable assessment in the absence of progression, will be included in the assessment of ORR. However, any responses, which occurred after a new anticancer therapy was received, will not be included. ORR is presented by percentages of responders.

Time frame:
On the first day of every 3 cycles (each cycle is 28 days) through study completion, an average of 2 years
Reported as:
Number · percentage of participants
Objective Response Rate Using RECIST Version 1.1 Criteria.
percentage of participantsDouble-Blind Phase - NirogacestatDouble-Blind Phase - Placebo
Objective Response Rate Using RECIST Version 1.1 Criteria.41 (29.8 to 53.8)8 (3.1 to 17.3)
Statistical analysis
  • Double-Blind Phase - Nirogacestat vs Double-Blind Phase - Placebo · Cochran-Mantel-Haenszel · p = < 0.001 (Two-sided p-value)
SecondaryChange From Baseline at Cycle 10 in the Brief Pain Inventory (BPI) Average Pain Intensity (API) Score.

The Brief Pain Inventory consists of 9 questions and utilizes a 11-point Numerical pain Rating Scale from 0-10 measuring severity from "no pain" to "pain as bad as you can imagine," with a 24-hour recall period. Average Pain Intensity is calculated as the 7-day average (when results on at least 4 days for a VISIT are available) of Brief Pain Inventory Question #3 - Worst Pain in last 24 hours. A lower score indicates greater pain relief. The minimum and maximum of the actual score are (0, 8) for Nirogacestat and (0,9) for Placebo, respectively. A positive change from Baseline value indicates worsening of Average Pain Intensity and a negative change from Baseline value indicates improvement of Average Pain Intensity. The minimum and maximum of change from baseline score are (-7, 3) for Nirogacestat and (-5, 5) for Placebo, respectively.

Time frame:
Daily for the last 7 days of every cycle (each cycle is 28 days) through study completion, an average of 2 years
Reported as:
Least squares mean · score on a scale
Change From Baseline at Cycle 10 in the Brief Pain Inventory (BPI) Average Pain Intensity (API) Score.
score on a scaleDouble-Blind Phase - NirogacestatDouble-Blind Phase - Placebo
Change From Baseline at Cycle 10 in the Brief Pain Inventory (BPI) Average Pain Intensity (API) Score.-1.583 (-2.157 to -1.009)-0.241 (-0.822 to 0.340)
Statistical analysis
  • Double-Blind Phase - Nirogacestat vs Double-Blind Phase - Placebo · Mixed Models Analysis · p = <0.001An unstructured covariance structure was used and degrees of freedom were estimated using the Kenward-Roger approximation.
SecondaryChange From Baseline at Cycle 10 in the GOunder/Desmoid Tumor Research Tumor Foundation (DTRF) DEsmoid Tumor Symptom Scale (DTSS) - Total Score

The DEsmoid Tumor Symptom Scale is an 11-point, numeric rating scale from 0 to 10 to measure severity from "none" to "as bad as you can imagine," with a 24-hour recall period. The Total Symptom Score is calculated as the mean of Pain items (Items 1-3) as a single score, then a mean of this with items 4-7). Weekly summary scores will be created by averaging the daily scores over the 7 days period prior to each visit. A weekly score will be derived only if 4 or more out of 7 days period have non-missing scores. The weekly summary score will be used in analyses. If no weekly summary score is calculable, the participant will have data considered as missing at that visit. Higher scores represent worse symptom severity. The minimum and maximum of the actual score are (0,7) for Nirogacestat and (0,10) for Placebo. A positive change from Baseline value indicated worsening of symptoms. The minimum and maximum of change from baseline are (-6,1) for Nirogacestat and (-4,5) for Placebo.

Time frame:
Daily for the last 7 days of every cycle (each cycle is 28 days) through study completion, an average of 2 years
Reported as:
Least squares mean · score on a scale
Change From Baseline at Cycle 10 in the GOunder/Desmoid Tumor Research Tumor Foundation (DTRF) DEsmoid Tumor Symptom Scale (DTSS) - Total Score
score on a scaleDouble-Blind Phase - NirogacestatDouble-Blind Phase - Placebo
Change From Baseline at Cycle 10 in the GOunder/Desmoid Tumor Research Tumor Foundation (DTRF) DEsmoid Tumor Symptom Scale (DTSS) - Total Score-1.110 (-1.569 to -0.651)0.457 (-0.009 to 0.923)
Statistical analysis
  • Double-Blind Phase - Nirogacestat vs Double-Blind Phase - Placebo · Mixed Models Analysis · p = <0.001An unstructured covariance structure was used and degrees of freedom were estimated using the Kenward-Roger approximation.
SecondaryChange From Baseline in the GOunder/Desmoid Tumor Research Foundation (DTRF) DEsmoid Tumor Impact Scale (DTIS) - Physical Functioning Domain Score

The items are evaluated on a 5-point Likert Scale ranging from "none of the time" to "all of the time" to measure frequency, with a 7-day recall period. The Physical Function Domain Score are calculated as the average Item 01 Moving, Item 02 Reaching (Freq), Item 06 Vigorous Activity, Item 7 Moderate Activity, and Item 08 Accomplished Less. Higher scores represent worst impact severity. The minimum and maximum of the actual score are (1, 5) for Nirogacestat and (1,5) for Placebo, respectively. A positive change from baseline value indicates worsening impact and a negative change from baseline value indicates improvement in impact. The minimum and maximum of change from baseline score are (-3, 0) for Nirogacestat and (-1, 2) for Placebo, respectively.

Time frame:
On the last day of every cycle (each cycle is 28 days) through study completion, average of 2 years.
Reported as:
Least squares mean · score on a scale
Change From Baseline in the GOunder/Desmoid Tumor Research Foundation (DTRF) DEsmoid Tumor Impact Scale (DTIS) - Physical Functioning Domain Score
score on a scaleDouble-Blind Phase - NirogacestatDouble-Blind Phase - Placebo
Change From Baseline in the GOunder/Desmoid Tumor Research Foundation (DTRF) DEsmoid Tumor Impact Scale (DTIS) - Physical Functioning Domain Score-0.613 (-0.808 to -0.418)0.094 (-0.113 to 0.300)
Statistical analysis
  • Double-Blind Phase - Nirogacestat vs Double-Blind Phase - Placebo · Mixed Models Analysis · p = <0.001An unstructured covariance structure was used and degrees of freedom were estimated using the Kenward-Roger approximation.
SecondaryChange From Baseline at Cycle10 in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status/Quality of Life (GHS/QoL) Scale.

The EORTC Quality of Life Questionnaire-Core 30 version 3.0 was used with a 7-day recall period. It consists of 30 questions with all items scored 1 ("not at all") to 4 ("very much") except for the 2 items contributing to the global health status/QoL, which are scored 1 ("very poor") to 7 ("excellent"). The instrument yields the following scales:5 functional scales, 3 symptom scales, and a global health status/quality of life scale. A high score for the global health status/QoL represents a high QoL. The minimum and maximum of the actual score are (33, 100) for Nirogacestat and (8,92) for Placebo, respectively. A positive change from baseline indicated improvement of global health status and a negative change from baseline value indicated worsening of global health status. The minimum and maximum of change from baseline score are (-58, 67) for Nirogacestat and (-67, 42) for Placebo, respectively.

Time frame:
Last day of every cycle (each cycle is 28 days) through study completion, an average of 2 years
Reported as:
Least squares mean · score on a scale
Change From Baseline at Cycle10 in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status/Quality of Life (GHS/QoL) Scale.
score on a scaleDouble-Blind Phase - NirogacestatDouble-Blind Phase - Placebo
Change From Baseline at Cycle10 in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status/Quality of Life (GHS/QoL) Scale.2.935 (-3.115 to 8.985)-8.466 (-15.065 to -1.867)
Statistical analysis
  • Double-Blind Phase - Nirogacestat vs Double-Blind Phase - Placebo · Mixed Models Analysis · p = 0.006An unstructured covariance structure was used and degrees of freedom were estimated using the Kenward-Roger approximation.
SecondaryChange From Baseline at Cycle 10 in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Physical Functioning

The EORTC Quality of Life Questionnaire-Core 30 version 3.0 was used with a 7-day recall period. It consists of 30 questions with all items scored 1 ("not at all") to 4 ("very much") except for the 2 items contributing to the global health status/QoL, which are scored 1 ("very poor") to 7 ("excellent"). The instrument yields the following scales:5 functional scales, 3 symptom scales, and a global health status/quality of life scale. A high score for a Physical functional scale represents a high/healthy level of functioning. The minimum and maximum of the actual score are (27, 100) for Nirogacestat and (7,100) for Placebo, respectively. A positive change from baseline indicated improvement of global health status and a negative change from baseline value indicated worsening of physical functioning scores. The minimum and maximum of change from baseline score are (-7, 40) for Nirogacestat and (-40, 27) for Placebo, respectively.

Time frame:
Last day of every cycle (each cycle is 28 days) through study completion, an average of 2 years
Reported as:
Least squares mean · score on a scale
Change From Baseline at Cycle 10 in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Physical Functioning
score on a scaleDouble-Blind Phase - NirogacestatDouble-Blind Phase - Placebo
Change From Baseline at Cycle 10 in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Physical Functioning9.143 (5.619 to 12.668)-5.225 (-9.060 to -1.390)
Statistical analysis
  • Double-Blind Phase - Nirogacestat vs Double-Blind Phase - Placebo · Mixed Models Analysis · p = <0.001An unstructured covariance structure was used and degrees of freedom were estimated using the Kenward-Roger approximation.
SecondaryChange From Baseline at Cycle 10 in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Role Functioning.

The EORTC Quality of Life Questionnaire-Core 30 version 3.0 was used with a 7-day recall period. It consists of 30 questions with all items scored 1 ("not at all") to 4 ("very much") except for the 2 items contributing to the global health status/QoL, which are scored 1 ("very poor") to 7 ("excellent"). The instrument yields the following scales:5 functional scales, 3 symptom scales, and a global health status/quality of life scale. A positive change from baseline indicated improvement of global health status and a negative change from baseline value indicated worsening of global health status and functioning scores. The minimum and maximum of change from baseline score are (-17, 83) for Nirogacestat and (-100, 50) for Placebo, respectively.

Time frame:
Last day of every cycle (each cycle is 28 days) through study completion, an average of 2 years
Reported as:
Least squares mean · score on a scale
Change From Baseline at Cycle 10 in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Role Functioning.
score on a scaleDouble-Blind Phase - NirogacestatDouble-Blind Phase - Placebo
Change From Baseline at Cycle 10 in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Role Functioning.13.293 (7.080 to 19.506)-5.590 (-12.320 to 1.139)
Statistical analysis
  • Double-Blind Phase - Nirogacestat vs Double-Blind Phase - Placebo · Mixed Models Analysis · p = <0.001An unstructured covariance structure was used and degrees of freedom were estimated using the Kenward-Roger approximation.

Adverse events

Collected over All SAEs and AEs were collected from the time of signing ICF until 30 days after the last dose of study treatment, an average of 1 years and 4 months and up to 2 years and 10 months. Medical occurrences that begin before the start of study treatment but after obtaining informed consent will be recorded as AEs.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-Blind Phase - Nirogacestat0/69 (0%)14/69 (20.3%)69/69 (100%)
Double-Blind Phase - Placebo1/72 (1.4%)8/72 (11.1%)69/72 (95.8%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventDouble-Blind Phase - NirogacestatDouble-Blind Phase - Placebo
Premature menopauseReproductive system and breast disorders3/690/72
SepsisInfections and infestations0/693/72
COVID-19Infections and infestations0/692/72
Atrial FibrillationCardiac disorders1/690/72
Abdominal painGastrointestinal disorders1/690/72
Small intestinal obstructionGastrointestinal disorders1/690/72
StomatitisGastrointestinal disorders1/690/72
CholecystitisHepatobiliary disorders1/690/72
Abdominal abscessInfections and infestations1/690/72
Abdominal infectionInfections and infestations1/690/72
Most frequent other events
Showing 10 of 71
Most frequent other events
EventDouble-Blind Phase - NirogacestatDouble-Blind Phase - Placebo
DiarrhoeaGastrointestinal disorders58/6925/72
NauseaGastrointestinal disorders37/6928/72
FatigueGeneral disorders35/6926/72
HypophosphataemiaMetabolism and nutrition disorders29/695/72
Rash maculo-papularSkin and subcutaneous tissue disorders22/694/72
StomatitisGastrointestinal disorders20/693/72
HeadacheNervous system disorders20/6911/72
Dermatitis acneiformSkin and subcutaneous tissue disorders15/690/72
VomitingGastrointestinal disorders14/6914/72
AlopeciaSkin and subcutaneous tissue disorders13/691/72

Baseline characteristics

Intent-To-Treat Population (All Randomized)

Age, Categorical
Age, Categorical(Participants)Double-Blind Phase - NirogacestatDouble-Blind Phase - PlaceboTotal
years — <=18 years000
years — Between 18 and 65 years6769136
years — >=65 years336
Age, Continuous
Age, Continuous(years)Double-Blind Phase - NirogacestatDouble-Blind Phase - PlaceboTotal
Mean37.5 ± 14.4337.0 ± 12.8937.2 ± 13.62
Sex: Female, Male
Sex: Female, Male(Participants)Double-Blind Phase - NirogacestatDouble-Blind Phase - PlaceboTotal
Female454792
Male252550
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Double-Blind Phase - NirogacestatDouble-Blind Phase - PlaceboTotal
Hispanic or Latino1910
Not Hispanic or Latino6755122
Unknown or Not Reported2810
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Double-Blind Phase - NirogacestatDouble-Blind Phase - PlaceboTotal
American Indian or Alaska Native000
Asian134
Native Hawaiian or Other Pacific Islander000
Black or African American459
White6454118
More than one race11011
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Double-Blind Phase - NirogacestatDouble-Blind Phase - PlaceboTotal
Canada437
Netherlands448
Belgium6511
United States405090
Italy5510
United Kingdom426
Germany7310
Tumor Location (Randomization Stratification Factor)
Tumor Location (Randomization Stratification Factor)(Participants)Double-Blind Phase - NirogacestatDouble-Blind Phase - PlaceboTotal
Intra-Abdominal171835
Extra-Abdominal5354107
08

Study locations

52 sites
  • Arkansas Children's Hospital
    Little Rock, Arkansas 72202, United States
  • USC/Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Ronald Regan UCLA Medical Center
    Los Angeles, California 90095, United States
  • Stanford Cancer Center
    Palo Alto, California 94304, United States
  • UCSF Mission Bay
    San Francisco, California 94158, United States
  • Sarcoma Oncology Research Center
    Santa Monica, California 90403, United States
  • University of Colorado Hospital-Anschutz Cancer Pavilion (ACP)
    Aurora, Colorado 80045, United States
  • Smilow Cancer Hospital at Yale-New Haven
    New Haven, Connecticut 06510, United States
  • Washington Cancer Institute at MedStar Washington Hospital Center
    Washington D.C., District of Columbia 20010, United States
  • Mayo Clinic Florida
    Jacksonville, Florida 32224, United States
  • Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Massachusetts General Hosptial (MGH)
    Boston, Massachusetts 02114, United States
  • Dana-Farber Cancer Institute (DFCI)
    Boston, Massachusetts 02215, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • Northwell Health
    Lake Success, New York 11042, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • DUMC/Duke Cancer Center
    Durham, North Carolina 27710, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center
    Columbus, Ohio 43210, United States
  • Oregon Health & Science University-Center for Health & Healing
    Portland, Oregon 97201, United States
  • Abramson Cancer Center at Pennsylvania Hospital
    Philadelphia, Pennsylvania 19106, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
  • Henry-Joyce Cancer Clinic
    Nashville, Tennessee 37232, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
  • University of Wisconsin Clinical Science Center
    Madison, Wisconsin 53792, United States
  • Froedtert Hospital & the Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Institut Jules Bordet-Medical Oncology
    Brussels, 1000, Belgium
  • Cliniques Universitaires Saint-Luc, Institut Roi Albert II
    Brussels, 1200, Belgium
  • UZ Gent
    Ghent, 9000, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G2M9, Canada
  • McGill University Health Centre
    Montreal, Quebec H4A3JI, Canada
  • Helios Klinikum Berlin-Buch
    Berlin, 13125, Germany
  • Universitaetsklinikum Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • Universitätsmedizin Mannheim
    Mannheim, D-68167, Germany
  • IRCCS Istituto Ortopedico Rizzoli
    Bologna, 40136, Italy
  • Istituto di Candiolo IRCCS Oncologia Medica
    Candiolo, 10060, Italy
  • Fondazione IRCCS Instituto Nazionale dei Tumori di Milano
    Milan, 20133, Italy
  • Policlinico Unvrsitario Campus Bio-Medico
    Roma, 00128, Italy
  • Radboud University Medical Centre
    Nijmegen, Gelderland 6525GA, Netherlands
  • The Netherlands Cancer Institute
    Amsterdam, 1066, Netherlands
  • Leiden University Medical Center (LUMC)
    Leiden, 23333, Netherlands
  • Department of Oncology, University College of London Hospital
    London, NW12PG, United Kingdom
  • The Royal Marsden NHS Foundation Trust
    London, SW36JJ, United Kingdom
09

References and documents

Publications

  • Ratan R, Kasper B, Alcindor T, Schoffski P, van der Graaf WTA, Federman N, Bui NQ, D'Amato G, Riedel RF, Attia S, Chawla S, Lim A, Tumminello B, Oton AB, Chu Y, Zhou S, Gounder M. Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial. J Clin Oncol. 2025 Dec;43(34):3646-3651. doi: 10.1200/JCO-25-00582. Epub 2025 Oct 20. PubMed 41115259 ↗
  • Gounder MM, Atkinson TM, Bell T, Daskalopoulou C, Griffiths P, Martindale M, Smith LM, Lim A. GOunder/Desmoid Tumor Research Foundation DEsmoid Symptom/Impact Scale (GODDESS(c)): psychometric properties and clinically meaningful thresholds as assessed in the Phase 3 DeFi randomized controlled clinical trial. Qual Life Res. 2023 Oct;32(10):2861-2873. doi: 10.1007/s11136-023-03445-7. Epub 2023 Jun 22. PubMed 37347393 ↗
  • Gounder M, Ratan R, Alcindor T, Schoffski P, van der Graaf WT, Wilky BA, Riedel RF, Lim A, Smith LM, Moody S, Attia S, Chawla S, D'Amato G, Federman N, Merriam P, Van Tine BA, Vincenzi B, Benson C, Bui NQ, Chugh R, Tinoco G, Charlson J, Dileo P, Hartner L, Lapeire L, Mazzeo F, Palmerini E, Reichardt P, Stacchiotti S, Bailey HH, Burgess MA, Cote GM, Davis LE, Deshpande H, Gelderblom H, Grignani G, Loggers E, Philip T, Pressey JG, Kummar S, Kasper B. Nirogacestat, a gamma-Secretase Inhibitor for Desmoid Tumors. N Engl J Med. 2023 Mar 9;388(10):898-912. doi: 10.1056/NEJMoa2210140. PubMed 36884323 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD supporting publicly available results will be evaluated for sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: IPD from completed trials will be publicly available within 6 months after all of the following events: Approval of a product/new indication by major authorities (FDA, EMA, PMDA if requested) with no pending submissions Public results via primary manuscript or trial registry disclosure Legal authority to share data Privacy protections are in place If approval is not sought or development is globally discontinued, data will be publicly available within 18 months after global trial completion. Further information on how to request data can be found on our website bit.ly/IPD21

Access criteria: Qualified researchers may propose access to IPD from sponsored trials via https://vivli.org/members/ourmembers/.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in Apr 2022, 35 months.

Results were first posted in Jun 2024, 2 years 2 months after primary completion. A results delay was requested in Mar 2023.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2018
First posted
Dec 24, 2018
StartActual
Apr 17, 2019
Primary completionActual
Apr 7, 2022
CompletionActual
Oct 17, 2024
Results delay requested
Mar 28, 2023
Results first posted
Jun 12, 2024
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03785964
Responsible party
Sponsor
First posted
Dec 24, 2018
Start date
Apr 17, 2019
Primary completion
Apr 7, 2022
Completion
Oct 17, 2024
Results posted
Jun 12, 2024
Last update
Aug 20, 2026

Study contacts

Bernd Kasper, MD
principal investigator · Mannheim University Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nirogacestat

Start the discussion